The Global Overview
Insilico Medicine Reverses Aging Markers
On September 7, 2026, Insilico Medicine, a Hong Kong biotech using generative AI for drug discovery, published a 42-patient Phase IIa trial reanalysis. Patients taking the AI-designed drug rentosertib showed a biological age reduction of 2.7 to 3.5 years (Nature Biotechnology). By computing both the target and the molecule, generative AI is becoming a structural deflationary force in pharma, collapsing traditional discovery timelines (Bloomberg).
US Trade Volatility Depresses Imports
The Centre for Economic Policy Research (CEPR), a network of European economists, found that confusion over 2025 US tariff policy caused import declines equaling the actual hikes. Arbitrary policy shifts act as a secondary barrier to trade, effectively doubling the economic friction of the tariffs themselves as capital hesitates amid uncertainty.
Apollo Faces Borrowing Premium
Portfolio entities of Apollo Global Management, a major American private equity and alternative asset firm, face borrowing costs one percentage point higher than peers (FT). Capital markets directly price in Apollo’s reputation for aggressive, hardline creditor treatment during debt restructurings, increasing the cost of capital for its acquired assets.
China Tourism Rebounds Cautiously
China’s tourism sector has rebounded into a trillion-dollar domestic driver, drawing tens of millions of foreign visitors annually (WSJ). Yet per-capita spending remains constrained, with travelers displaying tightfisted consumption amid global economic uncertainty. Stay tuned for the next Gist—your edge in a shifting world. The Gist remains independent and reader-supported. If you value news free from corporate or state interests, consider supporting our mission with a donation.
|
Leave a Reply